More Stories

Informist, Friday, Nov. 07, 2025

MUMBAI – Indian pharmaceutical stocks are likely to rise next week amid positive sentiment after most companies in the sector reported slightly better-than-expected earnings for the September quarter. Analysts said that the recently announced pharmacuetical agreement by the US under its Most-favoured-Nation policy might have a near-term impact on a few drug companies, but it might not reflect in their earnings as the glucagon-like peptide-1 drug gRevlimid is already being replaced by new launches of various companies. 

US President Donald Trump's administration on Thursday announced its newest pharmaceutical agreement under its Most-favoured-Nation policy, striking deals with innovators Novo Nordisk and Eli Lilly to sell their GLP-1 products at discounted prices. Senior US administration officials said the two manufacturers have agreed to sell their injectable GLP-1 products, Novo Nordisk's Wegovy and Lilly's Zepbound, for a monthly starting price of $245 for people on Medicare and Medicaid, as well as those who use the TrumpRX platform, expected to launch early next year, according to media reports.  

Investors will focus on September quarter earnings and management guidance from companies that are going to declare their results next week. Alkem Laboratories, Biocon, Glenmark Pharmaceuticals, Eris Lifesciences, IPCA Laboratories, and JB Chemical & Pharmaceuticals will announce their Jul-Sept earnings next week. 

The Nifty Pharma is expected to move in a broader range of 22000-22800 points, according to Anshul Jain, technical analyst at Laxmishree Investments and Securities. For the week ended Friday, the Nifty Pharma index ended flat at 22169.80 points. Wockhardt was the biggest gainer during the week, rising over 4% followed by IPCA Laboratories, which rose nearly 4%. Mankind Pharma fell over 5% and was the biggest loser in the index for the week. 

TOP HEADLINES

* Alembic Pharma gets US FDA final approval for Dasatinib tablet
* Earnings Review: Divi's Lab Q2 PAT, sales growth highest in 3 qtrs
* Torrent makes open offer for 26% stake in JB Chem at INR 1,639.18 per share
* Analyst Concall: Mankind Pharma says multiple parallel events hit Q2 revenue
* Sai Life Sciences Jul-Sept consol PAT doubles on year to INR 838.44 million
* Biocon board to meet Tue to mull raising funds via CPs
* Earnings Review: Lupin's Q2 consol PAT rises 73% on year, beats estimates
* Alivus Life Sciences Jul-Sept PAT rises 36% YoY to INR 1.3 billion
* Earnings Review: Mankind Pharma Q2 net profit down YoY for 4th straight qtr
* Analyst Concall: Zydus Life on track to achieve FY26 revenue, margin targets
* GSK Pharma Jul-Sept consol sales fall 3% YoY but net profit rises 2%
* Aarti Industries Jul-Sept PAT rises 84% YoY to INR 1.01 billion
* Earnings Review: Zydus Life's Q2 PAT growth robust on FX gain, US, India ops
* Zydus Life board OKs raising up to INR 50 bln via equity, NCDs, others
* Abbott India Jul-Sept PAT rises 16% YoY to INR 4.15 billion
* Earnings Review: US, India ops help Zydus Life to report robust PAT growth
* HC questions Patanjali on advt calling other cos' chyawanprash pdts as fraud
* HC quizzes Patanjali over 'fraud' remark in chyawanprash advt on Dabur plea
* US FDA grants orphan drug designation to Zydus Life's oral drug Desidustat
* Analyst Concall:Aurobindo Pharma arm Eugia unit to see US FDA audit in 8 mos
* Earnings Review:Aurobindo Pharma Q2 consol PAT up after 3 qtrs but below view
* Piramal Pharma posts INR 992.2-mln consol loss in Jul-Sep vs PAT year ago
* Syngene Intl Jul-Sep PAT falls 31.5% on year to INR 662 mln, sales rise 4%
* Analyst Concall: Sun Pharma sees FY26 R&D spend close to 6% of revenue
* Lupin gets establishment inspection report from US FDA for Pithampur unit
* Earnings Review: Sun Pharma Jul-Sept consol PAT up 3% on year, beats view
* Caplin Point Labs Jul-Sept consol PAT rises 18.1% YoY to INR 1.54 billion
* Zydus Life gets no observation from US FDA for mfg unit in Ahmedabad
* Granules India US arm gets one observation from US FDA post June inspection
* US FDA issues 9 observations on Jubilant Pharmova arms' mfg unit in Canada
* Zydus Life gets tentative US FDA nod for Budesonide delayed-release capsules
* Alembic Pharma Jul-Sept consol PAT rises 20.4% YoY to INR 1.85 billion
* Blue Jet Health Jul-Sept PAT down 10.6% on year as sales fall 20.5%
* Glenmark Pharma arm to launch sodium bicarbonate injection in US
* Akums Drugs gets patent for dual-release gastro-resistant composition
* Zydus Life board to Thursday mull raising up to INR 50 billion via equity
* Gland Pharma Jul-Sept consol PAT rises 12.3% YoY to INR 1.84 billion
* Cipla to acquire Inzpera Healthsciences for INR 1.11 billion
* Wockhardt posts INR 780-million consol PAT in Jul-Sept vs loss yr ago
* Ajanta Pharma Jul-Sept consol PAT rises over 20% YoY to INR 2.6 billion
* IPO Alert: Pine Labs sets price band at INR 210-INR 221 per share
* HC refuses to lift FSSAI ban on ORS tag on pdts not meeting medical norms
* MedPlus Health Jul-Sept consol PAT rises over 43% YoY to INR 555 mln
* Jubilant Pharmova Jul-Sept consol net profit rises 17% YoY to INR 1.2 bln

Following are the resistance and support levels for the stocks for next week as per calculations by Informist based on their prices on the National Stock Exchange:

End

Reported by P. Madhu Kumar

Edited by Deepshikha Bhardwaj

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2025. All rights reserved.